KITE 753
Alternative Names: KITE-753Latest Information Update: 12 Jun 2024
At a glance
- Originator Kite Pharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 27 Oct 2021 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA, Germany, Netherlands, United Kingdom (IV) (NCT04989803)
- 26 Oct 2021 Preclinical trials in B-cell lymphoma in USA (IV)